Vitamin D and Psoriasis — Does Oral Supplementation Ease Symptoms?

Topical creams and ointments containing vitamin D analogues have long been standard, prescription treatment for psoriasis — that much is well established in dermatology. Far less clear is whether ordinary oral vitamin D supplementation — the same kind many people take in autumn and winter for immunity — has any effect on the course of the disease. A 2021 systematic review and meta-analysis of randomized trials tried to answer that question, and the result is more ambiguous than it might seem at first glance.

AKdr Anna KowalczykAugust 27, 202611 min read

Table of contents

TL;DR — key takeaways

→Psoriasis is not eczema — an important distinction to start with
→Vitamin D in dermatology: a long-standing topic, but not in the form most people think of
→What exactly the 2021 systematic review examined
→Why the result is "ambiguous" rather than simply "negative"
→Limitations of this data
→What this means for someone with psoriasis considering supplementation
→Summary at a glance
→Our editorial recommendation

Psoriasis is not eczema — an important distinction to start with

Psoriasis and eczema (atopic dermatitis) are often treated as the same thing in popular perception — both present as red, itchy, flaking skin, and both follow a chronic course with periods of flare-ups and remission. In reality, these are two distinct diseases with different immunological underpinnings, different typical lesion appearance, and partly different treatment, which makes this distinction more than just a terminological curiosity.

Psoriasis is a chronic autoimmune-inflammatory disease in which the immune system — specifically overactive Th17 lymphocytes and their associated cytokines, mainly interleukin-17 and interleukin-23 — instructs skin cells to multiply several times faster than normal. Instead of the typical epidermal renewal cycle of about 28 days, in psoriasis it takes just 3-5 days, producing the characteristic, well-demarcated, thick, silvery-scaling plaques, most often on the elbows, knees, scalp, and lower back.

Myth

Psoriasis and eczema (atopic dermatitis) are essentially the same skin condition, just with different names.

Fact

These are two distinct disease entities. Eczema is more closely tied to the skin barrier and allergic-type reactions (elevated IgE, frequent co-occurrence with asthma and allergies), and its lesions are usually more diffuse, oozing, and intensely itchy. Psoriasis has an autoimmune basis rooted in the Th17/IL-17/IL-23 axis, and its lesions are typically well-demarcated, thick, and covered with silvery scale. Biologic treatments effective for one disease often don't work for the other — which itself confirms that the mechanisms are different.

Psoriasis affects about 2-3% of the world's population and, beyond the skin burden, carries an elevated risk of psoriatic arthritis, metabolic syndrome, and cardiovascular disease — so it's not merely a cosmetic issue, but a chronic systemic disease with a visible skin component.

Vitamin D in dermatology: a long-standing topic, but not in the form most people think of

The link between vitamin D and psoriasis isn't a new idea found on the internet — it's been well established in clinical dermatology for decades, just in a completely different form than a supplement in drops or a capsule. Topical vitamin D analogues, such as calcipotriol, have long been standard, prescription components of treatment for mild-to-moderate psoriasis, often combined with topical corticosteroids. They act locally on the skin, inhibiting excessive keratinocyte proliferation through the same VDR receptors we described in more detail in our article on vitamin D3.

The key distinction in this article

This article deals exclusively with oral vitamin D supplementation — that is, tablets, drops, and capsules taken systemically — not with topical vitamin D analogues applied directly to the skin as prescribed by a dermatologist. The efficacy of the latter in treating psoriasis is well established and is not the subject of this article or the study described below.

The question that genuinely remains open is a different one: given that topical vitamin D helps, does raising its level systemically — through ordinary oral supplementation, the same kind used preventively in autumn and winter — also translate into easing psoriasis symptoms? This question makes biological sense, because VDR receptors are found not only in the skin but also in the immune cells involved in the inflammatory process characteristic of psoriasis. But biological plausibility of a hypothesis is not the same as confirmation in clinical trials — and that's exactly what the systematic review described below tried to check.

What exactly the 2021 systematic review examined

Effectiveness of oral vitamin D supplementation in lessening disease severity among patients with psoriasis: a systematic review and meta-analysis of randomized controlled trials

Moderate evidence

Theodoridis X, Grammatikopoulou MG, Stamouli EM, Talimtzi P, Pagkalidou E, Zafiriou E, Haidich AB, Bogdanos DP · Nutrition · 2021

A systematic review and meta-analysis of randomized controlled trials (RCTs) evaluated the effect of oral vitamin D supplementation on psoriasis severity. Of 5,018 records screened, 4 studies were included in the qualitative analysis, and 3 studies in the quantitative meta-analysis proper. The main outcome assessed was the change in PASI (Psoriasis Area and Severity Index, the standard scale for psoriasis severity) after 6 months of supplementation. The initial analysis showed a small, statistically significant improvement: the mean difference (MD) was -0.92 PASI points (95% CI: -1.72 to -0.11). After applying a more conservative statistical correction (the Hartung-Knapp adjustment, standardly used in meta-analyses with a small number of component studies), the same mean difference of -0.92 was no longer statistically significant (the 95% CI widened to -2.21 to 0.38). The authors explicitly conclude that a beneficial effect of oral vitamin D supplementation in psoriasis patients could not be definitively confirmed.

View study

It's worth pausing on what this statistical correction actually means, because it's the crux of the whole result. Standard meta-analysis methods assume a certain number of component studies at which uncertainty estimation is reliable. With only three studies pooled, as in this case, the result is much more susceptible to the influence of a single study or to methodological differences between them. The Hartung-Knapp adjustment is precisely a way of estimating uncertainty more honestly and conservatively in such a situation — and it was this more cautious method that showed the effect could not be reliably distinguished from zero.

How to read this result honestly

Moderate evidence

This is not a study that "disproved" the hypothesis about vitamin D's role in psoriasis — it rather showed that current evidence from randomized trials is too scarce and too inconsistent to confirm a beneficial effect with sufficient statistical certainty. The direction of the result (a negative mean difference, i.e., improvement) was present in both versions of the analysis — only the certainty with which that direction could be considered a real effect, rather than chance, changed.

Why the result is "ambiguous" rather than simply "negative"

The difference between "the effect doesn't exist" and "the effect couldn't be confirmed with sufficient certainty" tends to blur in everyday language, but in research methodology it matters a great deal. Three studies in a meta-analysis is a small sample by evidence-based medicine standards — for comparison, conclusions about vitamin D's effect on respiratory infections, described in our article on vitamin D3, were based on data from more than 10,000 patients across dozens of trials. With only three studies, differences in vitamin D dosing, supplementation duration, participants' baseline 25(OH)D levels, or baseline psoriasis severity can easily shift the result one way or another.

The figure of -0.92 PASI points itself, even if it had turned out fully statistically significant, is also worth weighing against its clinical significance. The PASI scale typically ranges from 0 to 72, and a reduction of at least 75% from baseline (so-called PASI 75) is often used as a clinically meaningful improvement benchmark in trials of psoriasis drugs, including modern biologic therapies. A change of under one point, even in the best-case scenario from this meta-analysis, is a small effect compared to what's expected from drugs dedicated to psoriasis.

Limitations of this data

What this review does not prove

First, the pool of component studies was small — only 3 studies in the quantitative analysis — which itself limits the reliability of any conclusion, regardless of its direction. Second, these studies differed methodologically (dosing, duration, populations), which the review's authors themselves flag as a source of uncertainty. Third, the review covered only oral supplementation — it says nothing about topical vitamin D analogues, whose efficacy in treating psoriasis is established separately and far more solidly. Fourth, the studies assessed change in the PASI score rather than hard endpoints such as patient quality of life or long-term disease remission. Finally, the review did not separately analyze the subgroup of patients with baseline vitamin D deficiency — it's possible that in people with a genuine, confirmed 25(OH)D deficiency the effect of supplementation would be more pronounced than the averaged result across the whole studied population, but current data cannot settle this.

What this means for someone with psoriasis considering supplementation

Myth

Since topical vitamin D helps with psoriasis, taking vitamin D in tablet form should work even better because it acts on the whole body.

Fact

Topical vitamin D analogues act locally, at high concentrations directly at the site of the skin lesion, in a form optimized for effects on keratinocytes — this is a different delivery mechanism than raising overall 25(OH)D blood levels through an oral supplement. This systematic review shows that the effect of oral supplementation on the course of psoriasis, if it exists at all, is small and statistically uncertain — this assumption cannot simply be "carried over" from topical treatment to oral supplementation without separate evidence.

Practical takeaways for someone with psoriasis

The foundation of psoriasis treatment remains whatever a dermatologist prescribes — topical vitamin D analogues, topical corticosteroids, phototherapy, systemic or biologic drugs in more severe cases. No oral supplementation replaces this treatment
Checking your own 25(OH)D level with a blood test makes sense regardless of psoriasis — vitamin D deficiencies are common in Poland, as we describe in more detail in our article on vitamin D3, and correcting them makes sense for bone health and immunity, independent of any effect on the skin
If a blood test confirms an actual deficiency, correcting it with a dose matched to the result is reasonable on its own — but it shouldn't be treated as a psoriasis therapy with proven efficacy, since current data don't support that
Supplementing "just in case," at high doses, without a prior vitamin D level test, has no support from this review and carries a real, though rare at typical doses, risk of overdose with prolonged use of very high doses
Any supplementation should be treated as a possible, weakly supported addition to the main treatment, not an alternative to it — and discussed with the physician managing your psoriasis treatment, ideally a dermatologist

Summary at a glance

Question	Short answer
Does topical vitamin D help with psoriasis?	Yes — this is well-established, standard dermatological treatment, independent of this article's topic
Does oral vitamin D supplementation treat psoriasis?	There isn't sufficient evidence for this — a meta-analysis of 3 RCTs did not confirm a significant effect after a conservative statistical correction
Is it worth checking vitamin D levels with psoriasis?	Yes, but for general health reasons (bones, immunity), not as a proven therapy for psoriasis itself
Can supplementation replace treatment prescribed by a dermatologist?	No — there is no evidence for this, and psoriasis requires treatment tailored individually by a specialist
How many RCTs took part in this meta-analysis?	3 studies in the quantitative analysis, 4 in the qualitative one — a relatively small pool by evidence-based medicine standards

Vitamin D and psoriasis — what the data show

Our editorial recommendation

This topic is a good example of how easily two different things — proven topical treatment and uncertain oral supplementation — can blend into one oversimplified narrative like "vitamin D treats psoriasis." A rigorous approach requires separating these two facts: topical vitamin D analogues are a real, well-studied tool in a dermatologist's hands, while oral supplementation remains, at best, a potential, weakly supported addition, not a substitute for treatment.

Checking your vitamin D level makes sense for general health regardless of psoriasis — but I wouldn't recommend to anyone with this condition treating a pharmacy supplement as a substitute for treatment that actually has solid evidence of efficacy behind it.

Dr. Anna Kowalczyk, VitMode editorial team

Frequently asked questions

Psoriasis is an autoimmune-inflammatory disease rooted in the Th17/IL-17/IL-23 axis, producing well-demarcated, thick, silvery-scaling plaques. Eczema (atopic dermatitis) is more closely tied to the skin barrier and allergic reactions, and its lesions are usually more diffuse and oozing. These are distinct diseases requiring different therapeutic approaches.

No. Topical vitamin D analogues (e.g., calcipotriol) are established, prescription dermatological treatment that acts directly on the skin. This article and the meta-analysis it describes deal exclusively with oral vitamin D supplementation, for which the evidence of efficacy in psoriasis is much weaker and uncertain.

An analysis of 3 RCTs initially showed a small improvement in the PASI score after 6 months of oral supplementation (MD -0.92; 95% CI -1.72 to -0.11), but after applying a more conservative statistical correction (Hartung-Knapp), the result was no longer statistically significant (95% CI -2.21 to 0.38). The authors concluded that a beneficial effect could not be definitively confirmed.

Not quite — it means that current evidence from randomized trials is too scarce (only 3 studies) and too inconsistent to confirm an effect with sufficient statistical certainty. The direction of the result suggested improvement in both versions of the analysis, but the uncertainty is too large to treat this as a confirmed therapy.

Yes, but for reasons not directly related to psoriasis — vitamin D deficiencies are common in Poland and matter for bone health and immune function regardless of skin condition. If a blood test shows a deficiency, correcting it makes sense on its own, but it shouldn't be treated as a proven-effective therapy for psoriasis.

There's no evidence for this, and psoriasis is a chronic disease requiring treatment tailored individually by a dermatologist — from topical treatment, through phototherapy, to systemic and biologic drugs in more severe cases. Oral vitamin D, if it has any effect at all, could at most be a potential addition, never a substitute.

Of 5,018 records screened, the vast majority did not meet the inclusion criteria (e.g., they weren't randomized trials, involved topical rather than oral vitamin D, or didn't report relevant outcomes). Ultimately, 4 studies were included in the qualitative analysis and 3 in the quantitative meta-analysis, which is typical for narrowly defined research questions but also limits the statistical power of the final conclusion.

Sources

Theodoridis et al. 2021 — Nutrition

dr Anna Kowalczyk

PhD in Molecular Biology (University of Warsaw), 8 years researching cellular aging

Anna oversees the editorial process and scientific review of every publication in the knowledge base. She previously researched autophagy and mitochondrial biology.

Mężczyzna w szlafroku myjący twarz przy umywalce

TRT and Acne — Why Can Testosterone Cause Skin Problems?

Acne is the most common skin side effect of testosterone therapy — yet patients are rarely told exactly why it happens or what to actually do about it. We break down the sebaceous-gland mechanism step by step and lay out the full treatment ladder, from skincare to a dermatologist.

13 min

August 15, 2026

Wygodne łóżko w sypialni oświetlone miękkim porannym słońcem

Vitamin D3 and Longevity — Does a Deficiency Shorten Your Life?

Low vitamin D levels correlate with higher mortality across dozens of observational studies, yet the massive randomized VITAL trial found no evidence that supplementation extends life in people without a deficiency. We break down this apparent contradiction piece by piece.

13 min

August 20, 2026

Mężczyzna idący samotnie przez pole o wschodzie słońca

Vitamin D3 and Testosterone: Where Did This Popular Theory Come From, and Does It Hold Up?

"Vitamin D raises testosterone" is one of the most repeated claims in the biohacking community, resting largely on one small study from over a decade ago. A newer, better-designed, and significantly larger randomized trial, conducted on healthy men, gave an answer that should clearly cool those expectations — and it's exactly this contrast that makes this topic worth tracing carefully.

12 min

August 25, 2026

Zbliżenie dłoni wysypujących białe kapsułki z butelki suplementu

Daily Multivitamins: Do They Actually Help You Live Longer?

A daily multivitamin is one of the most purchased supplements in the world, driven by the belief that it's a simple "insurance policy" for a longer life. A massive cohort study covering nearly 400,000 US adults, followed for 27 years, shows the opposite of what you'd expect — people who regularly took a daily multivitamin had slightly higher, not lower, all-cause mortality than those who didn't.